近年来，随着人工智能技术的不断发展，医药、医疗行业正经历着一场深刻的变革。如在研发端，AI显然已成为突破“研发效率低、成本高”瓶颈的关键工具。值得注意的是，基于此，AI+制药领域的合作开始不断增多，研发领域也开始从小分子药物向多肽药物和双特异性抗体等拓展。如12月11日，腾盛博药宣布与OpenBench达成合作，将利用OpenBench的结构驱动人工智能平台，加速腾盛博药在创新药物发现领域的研发...
Source Link近年来，随着人工智能技术的不断发展，医药、医疗行业正经历着一场深刻的变革。如在研发端，AI显然已成为突破“研发效率低、成本高”瓶颈的关键工具。值得注意的是，基于此，AI+制药领域的合作开始不断增多，研发领域也开始从小分子药物向多肽药物和双特异性抗体等拓展。如12月11日，腾盛博药宣布与OpenBench达成合作，将利用OpenBench的结构驱动人工智能平台，加速腾盛博药在创新药物发现领域的研发...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.